HRA Pharma
Financials
Estimates*
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Revenues | 5.1m | 13.9m | 19.9m | 31.8m | 33.6m |
| % growth | - | 170 % | 43 % | 60 % | 6 % |
| EBITDA | <1m | <1m | <1m | 1.0m | <1m |
| % EBITDA margin | 2 % | 4 % | 4 % | 3 % | 1 % |
| Profit | <1m | <1m | <1m | <1m | (<1m) |
| % profit margin | 1 % | 2 % | 2 % | - | (1 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Growth Equity VC | ||
N/A | Acquisition | ||
| N/A | N/A | Growth Equity VC | |
€1.8b Valuation: €1.8b | Acquisition | ||
| Total Funding | - | ||
Related Content
Recent News about HRA Pharma
EditHRA Pharma, now a part of Perrigo Company plc, is a healthcare company focused on developing and marketing innovative products in women's health and rare diseases. Operating primarily in the European market, HRA Pharma serves a diverse range of clients including healthcare professionals, pharmacies, and patients. The company’s business model revolves around the development, approval, and distribution of pharmaceutical products, ensuring they meet stringent regulatory standards set by authorities such as the ANSM French health Authority. Revenue is generated through the sale of these specialized healthcare products, which are tailored to meet the needs of specific patient groups. HRA Pharma integrates ethical practices into its operations, striving to be an exemplary enterprise in the healthcare industry.
Keywords: women's health, rare diseases, pharmaceuticals, European regulations, healthcare professionals, pharmacies, patient-focused, ethical practices, regulatory compliance, innovative solutions.
